Skip to content

Tyra Biosciences, Inc. TYRA Free cash flow yield

Free cash flow yield at other companies

Incyte logo
IncyteINCY
8.1%+4.9pp
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
7.1%+2.4pp
UroGen Pharma logo
UroGen PharmaURGN
-19%-1.7pp
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-3.1%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
-17.7%-3.8pp
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-15.2%-4.4pp

Other financials

Income statement

See full
Operating income-$42.0M-31.9%
Net income-$39.3M-39.6%
EPS (diluted)-$0.64-36.2%

Balance sheet

See full
Cash & equivalents$85.0M-15.7%
Total debt$5.7M-6.9%
Total equity$387.6M+19.8%
Total assets$412.0M+20.0%

Cash flow

See full
Operating cash flow-$32.6M-27.9%
CapEx$88.0K+529%
Free cash flow-$32.7M-28.2%

Valuation

See full
Market cap$1.81B+318%

Returns & leverage

See full
Return on equity-36.9%+21.1pp
Debt / equity0.0×
Current ratio20.5×-2.3×

Where this comes from

Calculated from Tyra Biosciences, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Tyra Biosciences, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tyra Biosciences, Inc.'s free cash flow yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tyra Biosciences, Inc.'s free cash flow yield?
Tyra Biosciences, Inc. (TYRA) reported free cash flow yield of -5% in Q1 2026.
How has Tyra Biosciences, Inc.'s free cash flow yield changed year-over-year?
Tyra Biosciences, Inc.'s free cash flow yield increased by 66.7% year-over-year, from -14.9% to -5%.
What is the long-term trend for Tyra Biosciences, Inc.'s free cash flow yield?
Over 4 years (2021 to 2025), Tyra Biosciences, Inc.'s free cash flow yield has grown at a 12.9% compound annual growth rate (CAGR), from -4.2% to -6.8%.
What does free cash flow yield mean?
Trailing-twelve-month free cash flow divided by market capitalization at the quarter end. The cash return the business generates relative to its market price.